Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

The California-based biotech company's second-quarter revenue rose 9% from a year earlier to $9.2 billion. Adjusted earnings ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates.

(RTTNews) - Amgen Inc. (AMGN) announced that it swung to profit in its first quarter of 2025 from a loss last year, helped by higher revenues and an unrealized gain on its BeiGene, Ltd. equity ...

Analysts estimate that Amgen will report an earnings per share (EPS) of $5.26. The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody ...

Amgen Inc., the world’s largest biotechnology company, said third-quarter net income fell 8.1%, though sales increased for its two biggest drugs, Epogen and Neupogen. Net income fell to $329.9 ...

Amgen said it expects 2009 earnings, excluding items, of $4.55 to $4.75 per share on revenue of $14.8 billion to $15.2 billion. Wall Street is looking for earnings of $4.68 per share and revenue ...